News | March 26, 2012

MRI Techniques Improve Pulmonary Embolism Detection

March 26, 2012 - New research shows that the addition of two magnetic resonance imaging (MRI) sequences to a common MR angiography technique significantly improves detection of pulmonary embolism, a potentially life-threatening condition traditionally diagnosed through computed tomography (CT). Results of the study are published online in the journal Radiology.

Pulmonary embolism occurs when a blood clot — usually from the leg — travels to the lung and blocks the pulmonary artery or one of its main branches. CT angiography is the gold standard for diagnosis, but it exposes patients to ionizing radiation and iodinated contrast agent, which carries a risk of allergic reactions and kidney damage in some patients.

“MRI is developing much faster than CT,” said Diego R. Martin, M.D., Ph.D., head of the Department of Radiology at the University of Arizona College of Medicine in Tucson. “The images we're getting are already significantly better than they were a year ago. There is no doubt that in the future we will be able to offer a non-radiation-based alternative to CT for the diagnosis of pulmonary embolism.”

MRI has been used for pulmonary embolism detection in pregnant women and patients whose kidneys may be harmed by CT angiography contrast agents. However, the Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III) study, a major multi-center trial, found that centers had difficulty obtaining adequate quality MR pulmonary angiography (MRPA) for suspected pulmonary embolism. The PIOPED researchers determined that MRPA should be considered only at centers that routinely perform it and perform it well, and for patients who have contraindications to standard tests.         

In the new study, the research team assessed the impact of two additional MRI sequences on MRPA's accuracy. The two techniques—contrast-enhanced volumetric interpolated breath-hold examination (VIBE) and non-contrast true fast imaging with steady-state precession (true FISP)—complement MRPA, according to Martin.

The addition of VIBE provides a gray scale that enables readers to distinguish between the clot, or thrombus and the lung, which both appear dark on MRPA. 

“Also, VIBE is not time sensitive,” Martin said. “If the patient coughs, you can do it again. You don't have that option with MRPA.”

The true FISP test does not require contrast agent or a breath hold, an important consideration for embolism patients who often cannot hold their breath long enough for image acquisition on MRPA.

When Martin and his colleagues studied the three techniques on 22 patients with CTA diagnosis of pulmonary embolism, they found a sensitivity of 55 percent, 67 percent and 73 percent for MRPA, true FISP and VIBE, respectively. Combining all three MRI sequences improved the overall detection rate to 84 percent. Specificity was 100 percent for all detection methods except for MRPA, which demonstrated one false positive.

Martin hopes his findings stimulate discussion of a new, redesigned PIOPED study.

“PIOPED III did not answer the question of whether or not MRI is a useful alternative to CT, because it didn't use all the tools available,” he said.

The MRI sequences used in the study are offered on all the major vendor systems, according to Martin, with the entire three-sequence protocol taking only 15 minutes to set up and perform.

For more information: radiology.rsna.org

 

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init